GSK Plc EBIT

The latest EBIT for GSK is $19B as of September 2026. That compares with $5.3B in the prior-year period — up 261.1% year over year. That is below the Healthcare sector average of $2T. Investors often review this figure alongside GSK Plc's historical trend and sector peers before judging valuation or financial health.

Over the past year, GSK's EBIT moved from $5.3B to $19B — a 261.1% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in GSK Plc's operating scale or balance-sheet position.

Against Healthcare companies, GSK currently prints $19B for EBIT, while the sector average sits near $2T. That is roughly 99.0% below the sector mean. Large gaps often invite a closer look at GSK Plc's growth, margins, and balance sheet.

A EBIT figure of $19B for GSK is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $2T. Explore the charts below for those layers of context.

After noting GSK's EBIT ($19B), review year-over-year change from $5.3B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.